Sign inGet alerts
Request for proposalsFederal buyerWOSB

A--to expand the scope of the program by re-introducing the manufacture and distri

Verified 14 h agoAmended Aug 3, 2018
Responses dueNot stated
PostedFri, Aug 3, 20182 amendments, last Oct 7
Solicitation no.75N920-18-R-0070SAM.gov
Set-asideWOSBOnly firms holding this status can compete

What the agency is buying

by RFPFinder from the notice; the solicitation governs

The Federal agency is seeking to expand the Production Assistance for Cellular Therapy (PACT) III program. This presolicitation aims to re-introduce the manufacture and distribution of cellular products for human clinical trials.

Scope

  • Manufacture and distribution of cellular products
  • For human subjects in clinical trials under IND applications
WOSB set-aside
CompetitionCompetition unknown

1 signal behind this label (incumbent, repeat winner, short window, brand-name or sole-source language, prior sources sought). Pro shows them with sources.

From USAspending awards and the notice text, recomputed nightly (Oct 8). A signal, not a verdict.

How to get the bid documents

  1. Open the notice on SAM.gov
  2. Download the 1 attachment listed below from the source
  3. Submit before the deadline
Documents · 1 item, 1 file
  • DOC
    Click here to see more information about this opportunity on FedConnectexternal link
Open the original listing on SAM.gov

Details

Place of performance
Not stated
Buyer type
Federal
Notice type
Presolicitation
Solicitation no.
75N920-18-R-0070
NAICS
NAICS 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)): 108 open RFPs
Local presence
Not required
Amendments
2, last Oct 7
Contact
Williams, Jeffrey A.

Not stated in the notice: estimated value, contract type, period of performance. Check the bid documents.

Contact details from the source notice. Contact the buyer only about this solicitation.

Key dates

Fri, Aug 3, 2018Posted
Not statedQuestions due
Not statedResponses due
Amendment 1
Thu, Aug 9, 2018
Amendment 2
Wed, Oct 7, 2026 · The scope of the PACT III program has been expanded to include the manufacture and distribution of cellular products for use in human subjects participating in clinical trials.

Change log

verified Fri, Oct 9 · 12:30 AM ET
  1. Posted · PresolicitationFri, Aug 3, 2018 · 10:06 AM ET
  2. Amendment · New version of the notice posted at the sourceThu, Aug 9, 2018 · 1:12 PM ET
  3. Amendment · The scope of the PACT III program has been expanded to include the manufacture and distribution of cellular products for use in human subjects participating in clinical trials.Wed, Oct 7, 2026 · 12:35 AM ET
  4. Updated · description text changedThu, Oct 8, 2026 · 12:38 AM ET
  5. Updated · description text changedFri, Oct 9, 2026 · 12:33 AM ET
Report a problem

Notice as published

A--to expand the scope of the program by re-introducing the manufacture and distri

The primary purpose of the acquisition for the Production Assistance for Cellular Therapy (PACT) III program contract awards is to expand the scope of the program by re-introducing the manufacture and distribution of cellular products for use in human subjects participating in clinical trials under investigational new drug (IND) applications for the cell product.

Similar federal awards · NAICS 541715

USAspending.gov, last 36 months

4 awards matched · tier 3: NAICS 541715 at any agency; nothing from this office or agency. Most recent:

  • Jul 5CONNECTED ALLIANCES LLCINDUSTRIALIZATION OF COMPOSITE MANUFACTURING PHASE 1 PATHFINDERFA701426F0190 · DELIVERY ORDER · Department of the Air Force · ends Oct 31, 2026$750K
Pro

Pro shows every award with the recipient, amount, period and a link to the award record, plus a CSV export. $39/mo.

Sign in or upgrade

Awards for this key have not been synced yet.

Similar open RFPs

same NAICS 541715

Listing collected from SAM.gov. Always confirm requirements in the original solicitation before you bid.

Alert meView on SAM.gov